Want to see GB:RUA full AI Analyst Report?
RUA Stock Chart & Stats
24.00 p
1.00 p(4.17%)
At close: 4:00 PM EDT
24.00 p
1.00 p(4.17%)
Day’s Range― - ―
52-Week Range10.42 p - 28.90 p
Previous CloseN/A
Volume56.10K
Average Volume (3M)148.53K
Market Cap
£15.20M
Enterprise Value6.08 p
Total Cash (Recent Filing)£3.25M
Total Debt (Recent Filing)£794.00K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Jul 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£6.89M
Bulls Say, Bears Say
Bulls Say
Revenue ScaleMeaningful multi-year revenue scaling indicates growing product adoption and market penetration in specialized biomaterials. Sustained top-line expansion provides a foundation for operating leverage, enabling fixed-cost absorption and a credible pathway to durable profitability if trends continue.
High Gross MarginsConsistently strong gross margins reflect pricing power and favorable product mix in elastomeric biomaterials for implant and blood-contact applications. High margins support reinvestment in R&D and commercialization and create a structural buffer to absorb SG&A while pursuing scale.
Conservative LeverageLow leverage and a solid equity base reduce refinancing and solvency risk, giving the company flexibility to fund growth or weather cash-flow volatility. A conservative capital structure supports strategic investments and lowers the risk of forced dilution during continued scaling.
Bears Say
Negative Operating ProfitabilityA sustained negative EBIT margin signals the business has not yet converted sales into operating profits. Without consistent operating profitability, the company remains dependent on external funding to support growth and may face pressure to cut costs or slow expansion.
Negative Cash GenerationPersistent negative operating and free cash flow denotes ongoing cash burn despite improvement. This structural cash deficit increases reliance on financing, limits capacity for self-funded capex or commercialization, and raises dilution and execution risk if losses persist.
Weak Shareholder ReturnsA negative ROE shows equity capital is not yet producing returns, reflecting incomplete conversion of strong gross margins into net earnings. Until returns turn positive, attracting long-term equity investment and delivering shareholder value will remain challenged.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42 p and its highest was 28.90 p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £15.20M.
When is RUA Life Sciences’s upcoming earnings report date?
RUA Life Sciences’s upcoming earnings report date is Jul 19, 2027 which is in 340 days.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jun 30, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.042%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―